Clinical trial
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
NCT00097903 · BioNumerik Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00097903 |
|---|---|
| Title | Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer |
| Official title | Phase 1 Trial of Oral Karenitecin® in Patients With Solid Tumors" |
| Lead sponsor | BioNumerik Pharmaceuticals, Inc., Industry |
| Collaborators | Crown Bioscience Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Karenitecin (BNP1350) |
| Enrollment | 32 |
| Start date | May 1, 2004 |
| Primary completion | Oct 1, 2011 |
| Completion | May 1, 2013 |
| First posted | Dec 2, 2004 |
| Last update posted | Mar 12, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: